Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology

Authors Modi S, Van L, Gewirtzman A, Mendoza N, Bartlett B, Tremaine AM, Tyring S

Published 11 April 2008 Volume 2008:4(2) Pages 409—417

DOI https://doi.org/10.2147/TCRM.S1664

Sapna Modi1, Livia Van1, Aron Gewirtzman2, Natalia Mendoza2, Brenda Bartlett2, Anne Marie Tremaine2, Stephen Tyring3

1Baylor College of Medicine, Houston, TX, USA; 2Center for Clinical Studies, Houston, TX, USA; 3Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA

Abstract: Herpes simplex virus (HSV) infection is a highly prevalent condition responsible for significant morbidity and occasional mortality each year. Approximately half of all patients infected by HSV will experience at least one recurrence in their lifetime. For these recurrences, traditional therapy has included both suppressive and episodic treatment with nucleoside analogs. In regards to episodic treatment, 2- to 5-day oral regimens are best studied and most commonly reported. As with any medical condition having a well-understood mechanism of action and targeted treatment, therapeutic intervention is only as effective as allowed by patient compliance. Based on these concerns, recent studies have focused on shorter, less complicated, and more affordable options. This review delineates the evidence for single-day treatments of orolabial and genital herpes. Randomized, double-blind studies of both valacyclovir and famciclovir as single-day episodic therapy for HSV have been reported in the literature. Although no head-to-head studies between the drugs have been performed, both regimens produced significant improvement in healing time and symptom resolution over placebo. Single-day therapy for HSV infection is appealing for multiple reasons. First, it simplifies the regimen, increasing likelihood of patient compliance. Additionally, it allows complete delivery of the medication at the onset of symptoms, when viral replication is highest and intervention has greatest effect. Lastly, the reduced number of pills necessary for single versus multiple day therapy decreases the overall cost of treatment per episode, an important factor in modern-day healthcare.

Keywords: famciclovir, genital herpes, orolabial herpes, patient-initiated episodic therapy, single-day, antiviral

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Portal vein thrombosis in a patient with HCV cirrhosis and combined hemophilia A and thrombophilia V Leiden

Nikos Eleftheriadis, Pantelis Makris

Therapeutics and Clinical Risk Management 2010, 6:539-541

Published Date: 26 October 2010

Management of postoperative ileus: focus on alvimopan

Eric L Marderstein, Conor P Delaney

Therapeutics and Clinical Risk Management 2008, 4:965-973

Published Date: 10 October 2008

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Therapeutics and Clinical Risk Management 2008, 4:821-826

Published Date: 8 August 2008

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

F Braido, C Lagasio, IMG Piroddi, I Baiardini, GW Canonica

Therapeutics and Clinical Risk Management 2008, 4:353-361

Published Date: 11 April 2008

A review of nasal polyposis

Jonathan Ray Newton, Kim Wong Ah-See

Therapeutics and Clinical Risk Management 2008, 4:507-512

Published Date: 11 April 2008

Clinical and molecular aspects of glucocorticoid resistant asthma

Chris J Corrigan, Tuck-Kay Loke

Therapeutics and Clinical Risk Management 2007, 3:771-787

Published Date: 15 November 2007

Pharmacological causes of hyperprolactinemia

Daria La Torre, Alberto Falorni

Therapeutics and Clinical Risk Management 2007, 3:929-951

Published Date: 15 November 2007